1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration
| Autor: | Antonio Colombo, Roxana Mehran, Borislav Atzev, Deborah N. Kalkman, Zdeněk Coufal, Houng Bang Liew, Petr Hájek, Muhammad Munawar, Samantha Sartori, Martin Hudec, Robbert J. de Winter, Martin Mates, Peter den Heijer, Hazem M. Warda, Usman Baber, Tiong Kiam Ong, Melissa Aquino, Robert Gerber, Birgit Vogel, Paula Tejedor, Andrés Iñiguez, George Dangas, Petr Kala, Bryan P. Yan, Ahmed Khashaba, Jaya Chandrasekhar, Borislav Borisov, Jarosław Wójcik, Michael S. Lee, Alexandr Schee |
|---|---|
| Přispěvatelé: | Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Heart failure & arrhythmias |
| Rok vydání: | 2020 |
| Předmět: |
Target lesion
medicine.medical_specialty Asia Time Factors Geographical differences medicine.medical_treatment Endothelial progenitor cell capture Coronary Artery Disease 030204 cardiovascular system & hematology Prosthesis Design Percutaneous coronary intervention Anti-CD34+ antibody coating 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Statistical significance medicine Humans 030212 general & internal medicine Myocardial infarction COMBO stent Geography business.industry Incidence (epidemiology) Stent Drug-Eluting Stents equipment and supplies Clopidogrel medicine.disease Europe Treatment Outcome Conventional PCI Female Stents Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | International journal of cardiology, 307, 17-23. Elsevier Ireland Ltd Web of Science |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2020.01.045 |
| Popis: | Background The COMBO drug-eluting stent combines sirolimus-elution from a biodegradable polymer with an anti-CD34+ antibody coating for early endothelialization. Objective We investigated for geographical differences in outcomes after percutaneous coronary intervention (PCI) with the COMBO stent among Asians and Europeans. Methods The COMBO Collaboration is a pooled patient-level analysis of the MASCOT and REMEDEE registries of all-comers undergoing attempted COMBO stent PCI. The primary outcome was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR). Results This study included 604 Asians (17.9%) and 2775 Europeans (82.1%). Asians were younger and included fewer females, with a higher prevalence of diabetes mellitus but lower prevalence of other comorbidities than Europeans. Asians had a higher prevalence of ACC/AHA C type lesions and received longer stent lengths. More Asians than Europeans were discharged on clopidogrel (86.5% vs 62.8%) rather than potent P2Y12 inhibitors. One-year TLF occurred in 4.0% Asians and 4.1% of Europeans, p = 0.93. The incidence of cardiac death was higher in Asians (2.8% vs. 1.3%, p = 0.007) with similar rates of TV-MI (1.5% vs. 1.2%, p = 0.54) and definite stent thrombosis (0.3% vs. 0.5%, p = 0.84) and lower incidence of TLR than Europeans (1.0% vs. 2.5%, p = 0.025). After adjustment, differences for cardiac death and TLR were no longer significant. Conclusions In the COMBO collaboration, although 1-year TLF was similar regardless of geography, Asians experienced higher rates of cardiac death and lower TLR than Europeans, while incidence of TV-MI and ST was similar in both regions. Adjusted differences did not reach statistical significance. Clinicaltrial.gov identifier-numbers NCT01874002 (REMEDEE Registry), NCT02183454 (MASCOT registry). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect